Yeh Tsung-Jang, Yang Ching-I, Huang Chien-Tzu, Wang Min-Hung, Chuang Tzer-Ming, Ke Ya-Lun, Gau Yuh-Ching, Du Jeng-Shiun, Wang Hui-Ching, Cho Shih-Feng, Lee Ching-Ping, Hsu Chin-Mu, Hsiao Hui-Hua, Liu Yi-Chang
Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
J Fungi (Basel). 2022 Apr 16;8(4):408. doi: 10.3390/jof8040408.
Infection is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) especially cytomegalovirus (CMV) infection and invasive fungal infection (IFI). Taiwan is a high CMV seroprevalence area. Our study aimed to evaluate the incidence, risk factors, the impact on survival of CMV infection (including reactivation and disease) and the association of CMV infection and IFI in recipients after allo-HSCT during the first 100 days after transplantation. This was a retrospective study including 180 recipients of allo-HSCT. A total of 99 patients had CMV reactivation, and nine patients had CMV diseases. There were more mismatched donors, more ATG usage and more transplantation from CMV IgG-negative donor in patients with CMV reactivation. There was no survival difference in patients with or without CMV reactivation. A total of 34 patients had IFIs, and IFI after allo-HSCT was associated with significantly inferior survival. Patients with CMV reactivation did not increase the incidence of overall IFI, but they did result in more late-onset (>40 days) IFI (p = 0.056). In this study, we demonstrated real-world data of CMV infection and IFI from a high CMV seroprevalence area.
感染是异基因造血干细胞移植(allo-HSCT)后的主要并发症,尤其是巨细胞病毒(CMV)感染和侵袭性真菌感染(IFI)。台湾是CMV血清阳性率较高的地区。我们的研究旨在评估allo-HSCT受者移植后前100天内CMV感染(包括再激活和疾病)的发生率、危险因素、对生存的影响以及CMV感染与IFI的关联。这是一项回顾性研究,纳入了180例allo-HSCT受者。共有99例患者发生CMV再激活,9例患者发生CMV疾病。CMV再激活患者中不匹配供者更多、抗胸腺细胞球蛋白(ATG)使用更多且来自CMV IgG阴性供者的移植更多。CMV再激活患者与未发生CMV再激活的患者在生存方面无差异。共有34例患者发生IFI,allo-HSCT后的IFI与显著较差的生存相关。CMV再激活患者并未增加总体IFI的发生率,但确实导致更多迟发性(>40天)IFI(p = 0.056)。在本研究中,我们展示了来自CMV血清阳性率较高地区的CMV感染和IFI的真实世界数据。